Rhythm Biosciences Limited
ASX:RHY 주식 보고서
Rhythm Biosciences 미래 성장 현재 Rhythm Biosciences 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.
주요 정보 Healthcare 수익 성장 26.1% 매출 성장률 n/a 향후 자기자본 수익률 n/a 애널리스트 커버리지 None
마지막 업데이트 n/a
최근 미래 성장 업데이트
모든 업데이트 표시
Rhythm Biosciences Ltd Appoints Gavin Fox-Smith as Independent Non-Executive Director Effective 2 December 2024 Nov 11
Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024 Sep 10
New minor risk - Share price stability Sep 06
New major risk - Financial position Aug 31
New major risk - Shareholder dilution Mar 31
New minor risk - Shareholder dilution Mar 26 Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million. Mar 22
Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million. Feb 09
Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director Dec 29
Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024 Dec 14
New major risk - Share price stability Dec 07
Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans? Dec 06
New minor risk - Share price stability Oct 12
New minor risk - Shareholder dilution Sep 13
Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023 Sep 01
New minor risk - Financial data availability Aug 26
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate Aug 09
Executive Chairman recently bought AU$248k worth of stock May 16
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely Apr 11
Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director Jan 31
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation Dec 02
Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited Nov 29
Less than half of directors are independent Nov 16
Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022 Oct 31 Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer
Executive Chairman recently sold AU$6.5m worth of stock Sep 10
Executive Chairman exercised options to buy AU$459k worth of stock. Aug 31
Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021) Aug 30
Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021) Aug 30
Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers Jul 19
Less than half of directors are independent Apr 27
Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ® Apr 04
Rhythm Biosciences Ltd Announces Executive Changes Feb 25
Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding Jan 06
Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7) Sep 23
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely Jul 19
Non-Executive Director David White has left the company Jul 15
Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial Jun 16
Rhythm Biosciences Betters ColoSTAT Results May 08
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation Mar 03
New 90-day high: AU$1.64 Mar 01
Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site Feb 11
New 90-day high: AU$1.56 Feb 10
Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites Jan 20
New 90-day high: AU$1.38 Jan 15
New 90-day high: AU$0.88 Dec 31
Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit Dec 04
Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares? Dec 03
New 90-day high: AU$0.28 Nov 10
New 90-day high: AU$0.21 Sep 24
Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial Sep 24
New 90-day high - AU$0.20 Sep 15
Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million. Aug 29
Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding Jul 23
이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Rhythm Biosciences 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.
SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.
수익 및 매출 성장 예측 ASX:RHY - 애널리스트의 미래 추정치 및 과거 재무 데이터 (AUD Millions ) 날짜 수익 수익 잉여 현금 흐름 작전 현금 평균 애널리스트 수 6/30/2024 2 -7 -6 -6 N/A 3/31/2024 2 -8 -7 -7 N/A 12/31/2023 2 -9 -8 -8 N/A 9/30/2023 3 -8 -8 -8 N/A 6/30/2023 3 -8 -7 -7 N/A 3/31/2023 3 -8 -7 -7 N/A 12/31/2022 3 -8 -6 -6 N/A 9/30/2022 3 -9 -6 -6 N/A 6/30/2022 2 -9 -7 -6 N/A 3/31/2022 2 -9 -6 -6 N/A 12/31/2021 2 -9 -6 -6 N/A 9/30/2021 2 -8 -6 -6 N/A 6/30/2021 1 -7 -5 -5 N/A 3/31/2021 1 -5 -4 -4 N/A 12/31/2020 1 -4 -3 -3 N/A 9/30/2020 1 -4 -3 -3 N/A 6/30/2020 0 -4 -3 -3 N/A 3/31/2020 0 -4 -3 -3 N/A 12/31/2019 1 -3 -3 -3 N/A 9/30/2019 1 -3 -3 -3 N/A 6/30/2019 1 -3 -3 -3 N/A 3/31/2019 1 -3 -3 -3 N/A 12/31/2018 0 -3 -2 -2 N/A 9/30/2018 0 -2 -2 -2 N/A 6/30/2018 N/A -2 -2 -2 N/A
자세히 보기
애널리스트 미래 성장 예측
수입 대 저축률: RHY 의 예상 수익 증가율이 절약률 ( 2.6% )보다 높은지 판단하기에는 데이터가 부족합니다.
수익 vs 시장: RHY 의 수익이 Australian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.
고성장 수익: RHY 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.
수익 대 시장: RHY 의 수익이 Australian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.
고성장 수익: RHY 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.
미래 자기자본 수익률
미래 ROE: RHY 의 자기자본수익률 이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
